Table 2 Difference in lab values between the study groups based on presence of hepatopancreatic injury (t test; p< 0.0001 for all labs)
From: Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA
Variable (mean, standard deviation) | Hepatopancreatic injury not present (N = 16,865) | Hepatopancreatic injury present (N = 28,495) |
|---|---|---|
Alanine transaminase (ALT) | 25.28, 10.89 | 85.38, 89.76 |
Aspartate transaminase (AST) | 25.38, 7.23 | 94.53, 89.76 |
Alkaline phosphatase (AlkP) | 89.96, 38.36 | 109.5, 61.38 |
Total Bilirubin | 0.5875, 0.3565 | 0.8512, 0.6009 |
Albumin | 2.98, 0.69 | 2.71, 0.72 |
Prothrombin time (PT) | 13.35, 5.05 | 13.99, 5.30 |
Lipase | 116.5, 79.04 | 226, 321.4 |
Lactate dehydrogenase (LDH) | 283.3, 131.9 | 474.0, 257.2 |